Benjamin Seides, MD
Pulmonary Disease · Winfield, ILNPI 1770648073
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $144,267 of the $203,388 with a category attached, or 70.9%. 18 manufacturers reported payments, led by Johnson & Johnson at 32.0% of the total. Reporting peaked in 2024 at $50,310 and has fallen 65.1% since, to $17,535 in 2025. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $726.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$65K
- Intuitive Surgical$37K
- Ethicon Endo-surgery Inc.$31K
- GE HealthCare$27K
- Pulmonx Corporation$21K
- Medical Device Business Services, Inc.$10K
- plus $13K from 12 others
Across 48 payments — averaging $2854.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$87K
- Pulmonx Corporation$50K
What the payments were for
- Consulting fees$144,26771%
- Speaking & faculty fees$18,4139%
- Travel & lodging$22,90411%
- Food & beverage$6,8093%
- Education$10,9865%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 94 | $65,130 |
| Intuitive Surgical | 88 | $36,733 |
| Ethicon Endo-surgery Inc. | 12 | $30,823 |
| GE HealthCare | 14 | $26,856 |
| Pulmonx Corporation | 30 | $21,034 |
| Medical Device Business Services, Inc. | 7 | $9,595 |
| Olympus Corporation | 11 | $6,366 |
| Steris Corporation | 4 | $2,127 |
| Veran Medical Technologies, Inc. | 4 | $1,948 |
| Olympus America Inc. | 5 | $1,485 |
| Olympus Medical Systems Corporation | 2 | $821 |
| Boston Scientific | 1 | $109 |
| Auris Health, Inc. | 3 | $98 |
| Medtronic | 1 | $83 |
| AstraZeneca | 1 | $79 |
| Covidien LP | 1 | $51 |
| Philips North America LLC | 1 | $27 |
| Vapotherm Inc | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$98,185
- OEC$26,697
- DA VINCI SP$18,057
- Da Vinci Surgical System$17,324
- Pulmonx Endobronchial Valve EBV$10,767
- ZEPHYR ENDOBRONCHIAL VALVE$9,765
- CHARTIS CATHETER$6,165
- ZEPHYR DELIVERY CATHETER$6,165
- PULMONX CHARTIS TABLET CONSOLE$6,165
- MONARCH$5,671
- TRUFREEZE$2,066
- EVIS EXERA II ULTRASONIC BRONCHOFIBERVIDEOSCOPE$1,095
- SPiN Vision Video Processor$365
- Single Use Aspiration Needle NA-U200H$365
- Spin$123
- ACQUIRE$109
How this compares
$203,388 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $85,622 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 101 | $55,431 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,476 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $13,597 |
| Spiriva HandihalerTiotropium Bromide | 15 | $11,552 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $8,041 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $2,074 |
| Ventolin HfaAlbuterol Sulfate | 18 | $986 |
| Doxycycline Hyclate | 15 | $157 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $122 |
| Levofloxacin | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere | $79 | $16,47626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Winfield
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Danish ThameemChampaign$353K
- Bradford BemissMaywood$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.